Nephrocare Healt

Why is Nephrocare Health Services Ltd falling/rising?

As of 08-Jul, Nephrocare Health Services Ltd's stock price is at 641.30, down 2.34%, continuing a downward trend with a 5.48% decline over the past week. Despite being net-debt free and having increased institutional investment, the stock faces significant selling pressure and reduced investor participation.

As of 08-Jul, Nephrocare Health Services Ltd's stock price is falling, currently at 641.30, which reflects a decrease of 15.35 or 2.34%. The stock has been on a downward trend, losing 4.5% over the last two days. Additionally, the stock's performance over the past week shows a decline of 5.48%, contrasting with a minor decrease of 0.54% in the benchmark Sensex. <BR><BR>Today's trading activity indicates that the stock reached an intraday low of Rs 631.9, which is a drop of 3.77%. The weighted average price suggests that more volume was traded closer to this low price, indicating a lack of strong buying interest at higher levels. Furthermore, there has been a significant reduction in investor participation, with delivery volume falling by 50.74% compared to the five-day average. <BR><BR>Despite these negative indicators, it is worth noting that the company is net-debt free and has shown healthy long-term growth potential, with institutional investors increasing their stake by 1.18% in the last quarter. However, these positive factors have not been sufficient to counteract the current downward pressure on the stock price.

Which are the latest news on Nephrocare Healt?

Should I buy, sell or hold Nephrocare Health Services Ltd?

What does Nephrocare Healt do?

Nephrocare Health Services Ltd is a small-cap healthcare company that reported net sales of 266 Cr and a net profit of 30 Cr for March 2026. Key metrics include a P/E ratio of 93.00 and a market cap of INR 7,195 Cr.

Overview: <BR>Nephrocare Health Services Ltd operates in the healthcare services industry and is classified as a small-cap company.<BR><BR>History: <BR>The incorporation year is not provided, and there are no status changes mentioned. The latest quarterly results reported are for March 2026, showing net sales and profit.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 266 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 30 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 7,195 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 93.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.31 <BR>Return on Equity: 6.88% <BR>Price to Book: 6.47 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: Not available. <BR>Email: Not available. <BR>Website: Not available.

How big is Nephrocare Healt?

As of 10th June, Nephrocare Health Services Ltd has a market capitalization of 7,195.00 Cr, with net sales of 990.26 Cr and a net profit of 78.01 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Nephrocare Health Services Ltd has a market capitalization of 7,195.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 990.26 Cr, while the sum of Net Profit for the same period is 78.01 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 584.11 Cr, and Total Assets are valued at 975.89 Cr.

Who are the peers of the Nephrocare Healt?

Nephrocare Healt's peers include Poly Medicure, Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs, Krsnaa Diagnost., Suraksha Diagno., and Laxmi Dental. Thyrocare Tech. leads with a 1-year return of 61.22%, while Laxmi Dental has the lowest at -48.44%.

Peers: The peers of Nephrocare Healt are Poly Medicure, Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs, Krsnaa Diagnost., Suraksha Diagno., Laxmi Dental.<BR><BR>Quality Snapshot: Excellent management risk is observed at Poly Medicure, Vijaya Diagnost., Metropolis Healt, and Thyrocare Tech., while Average management risk is found at Indegene, Vimta Labs, Krsnaa Diagnost., and Laxmi Dental. Below Average management risk is noted for Suven Life Scie. Good growth is seen at Suraksha Diagno. and Laxmi Dental, while Below Average growth is present in Poly Medicure, Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs, Krsnaa Diagnost., and the rest. Excellent capital structure is held by Poly Medicure, Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., Vimta Labs, Krsnaa Diagnost., and Laxmi Dental, while Below Average capital structure is noted for Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Thyrocare Tech. at 61.22%, while Laxmi Dental has the lowest at -48.44%. Nephrocare Healt's 1-year return is not available for comparison. Additionally, the peers with negative six-month returns include Krsnaa Diagnost., Suraksha Diagno., and Laxmi Dental.